Table 3.
ATRIA ≤3 (n=7440) | MD Low Risk (n=5982) | ATRIA = 4 (n=905) | MD Intermediat e Risk (n=3393) | ATRIA ≥5 (n=1749) | MD High Risk (n=719) | |
---|---|---|---|---|---|---|
Age (year) | 73.5 (65-81) | 73 (64-80) | 68 (63-72) | 78 (71-83) | 82 (78-86) | 78 (71-84) |
Female | 40 | 41 | 44 | 44 | 51 | 48 |
Race | ||||||
White | 90 | 88 | 82 | 91 | 90 | 89 |
Black or African American | 4.4 | 5.5 | 11 | 4.2 | 4.6 | 4.9 |
Hispanic | 4.2 | 4.8 | 5.2 | 3.2 | 3.7 | 4.2 |
Other | 1.4 | 1.4 | 1.4 | 1.3 | 1.4 | 1.8 |
Hypertension | 80 | 80 | 99 | 87 | 88 | 87 |
Diabetes | 27 | 27 | 40 | 33 | 33 | 37 |
Prior GI Bleed | 5.6 | 6.1 | 15 | 11 | 20 | 22 |
Anemia | 0.9 | 14 | 54 | 23 | 73 | 32 |
Liver Disease | 1.8 | 1.8 | 3.2 | 1.8 | 1.8 | 3.5 |
Alcohol Abuse | 4.4 | 3.9 | 5.2 | 3.9 | 2.1 | 6 |
Estimated GFR (mL/min/1.73 m2) | 69 (56-85) | 70 (56-85) | 65 (49-79) | 64 (50-79) | 52 (35-69) | 60 (43-74) |
Hemoglobin (g/dL) | 13.8 (12.7-14.8) | 13.7 (12.5-14.8) | 12.6 (11.2-13.8) | 13.3 (12-14.4) | 12 (10.9-13.1) | 12.8 (11.4-14.1) |
Type of AF | ||||||
New Onset | 4.8 | 5.6 | 5.4 | 3.6 | 3.9 | 2.4 |
Paroxysmal | 52 | 52 | 49 | 48 | 47 | 48 |
Persistent | 17 | 16 | 18 | 17 | 15 | 21 |
Longstanding Persistent | 26 | 26 | 28 | 31 | 34 | 28 |
Oral Anticoagulation | ||||||
None | 23 | 27 | 26 | 17 | 27 | 32 |
Warfarin | 72 | 68 | 69 | 78 | 71 | 65 |
Dabigatran | 5.3 | 5.2 | 5.2 | 4.7 | 2.7 | 2.8 |
CHADS2 Risk Score, mean (SD) | 2.12(1.27) | 2.03(1.24) | 2.19(1.13) | 2.6(1.25) | 2.99(1.2) | 2.87(1.31) |
ATRIA Score | ||||||
Low (0-3) | 100 | 78 | 0 | 69 | 0 | 58 |
Intermediate (4) | 0 | 8.8 | 100 | 8.8 | 0 | 11 |
High (5 or more) | 0 | 13 | 0 | 22 | 100 | 30 |
Site Provider | ||||||
Cardiology | 64 | 67 | 70 | 65 | 69 | 54 |
Electrophysiology | 17 | 14 | 12 | 14 | 10 | 28 |
Primary Care Specialty | 20 | 19 | 18 | 21 | 20 | 18 |
Values are presented as % or median (interquartile range), except where noted.
GI: gastrointestinal; GFR: glomerular filtration rate; AF: atrial fibrillation; SD: standard deviation.